Analysis of underlying diseases and prognosis factors associated with Pneumocystis carinii pneumonia in immunocompromised HIV-negative patients

European Journal of Clinical Microbiology and Infectious Diseases

Volumn 21, Issue 7, 2002, Pages 523-531

  Roblot, F ^a   Godet, C ^a   Le Moal, G ^a   Garo, B ^b   Faouzi Souala, M ^c   Dary, M ^d   De Gentile, L ^e   Gandji, J ^f   Guimard, Y ^g   Lacroix, C ^a   Roblot, P ^a   Becq Giraudon, B ^a  

^a POITIERS UNIVERSITY HOSPITAL   (France)

^b BREST UNIVERSITY HOSPITAL   (France)

^c RENNES UNIVERSITY HOSPITAL   (France)

^d NANTES UNIVERSITY HOSPITAL   (France)

^e ANGERS UNIVERSITY HOSPITAL   (France)

^f LIMOGES UNIVERSITY HOSPITAL   (France)

^g UNIVERSITY HOSPITAL OF TOURS   (France)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; CORTICOSTEROID; CYTOTOXIC AGENT; LACTATE DEHYDROGENASE;

ADOLESCENT; ADULT; AGED; ARTICLE; ARTIFICIAL VENTILATION; BLOOD DISEASE; BONE MARROW TRANSPLANTATION; BREATHING RATE; CLINICAL FEATURE; CONTROLLED STUDY; CORTICOSTEROID THERAPY; CYST; DIAGNOSTIC PROCEDURE; DISEASE ASSOCIATION; DISEASE COURSE; ENZYME BLOOD LEVEL; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; IMMUNE DEFICIENCY; INFLAMMATION; INTENSIVE CARE UNIT; LONG TERM CARE; LUNG LAVAGE; MAJOR CLINICAL STUDY; MALE; MORTALITY; NONHUMAN; ORGAN TRANSPLANTATION; PNEUMOCYSTIS CARINII; PNEUMOCYSTIS PNEUMONIA; PRIORITY JOURNAL; PROGNOSIS; PROTEIN DETERMINATION; PULSE RATE; RETROSPECTIVE STUDY; SOLID TUMOR; SURVIVAL;

ADOLESCENT; ADULT; AGED; AUTOIMMUNE DISEASES; BONE MARROW TRANSPLANTATION; FEMALE; HIV SERONEGATIVITY; HUMANS; IMMUNOCOMPROMISED HOST; INFLAMMATION; MALE; MIDDLE AGED; NEOPLASMS; OPPORTUNISTIC INFECTIONS; ORGAN TRANSPLANTATION; PNEUMOCYSTIS; PNEUMONIA, PNEUMOCYSTIS; PROGNOSIS; RETROSPECTIVE STUDIES; RISK FACTORS;

EID: 0036046406     PISSN: 09349723     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10096-002-0758-5     Document Type: Article

References (59)

1. Molecular epidemiology of human pneumocystosis
2. Pneumocystis carinii pneumonia
3. Descriptive epidemiology of interstitial Pneumocystis pneumonia: An analysis of 107 cases from the United States, 1965-1967
4. Pneumocystis carinii pneumonia in patients with connective tissue diseases. The role of hospital experience in diagnosis and mortality
5. Pneumocystis carinii pneumonia in human immunodeficiency virus (HIV)-positive and HIV-negative immunocompromised patients
6. Current issues in the epidemiology, transmission and reactivation of Pneumocystis carinii
7. Prophylaxis for Pneumocystis carinii pneumonia in solid organ transplant recipients. As long as the pros outweigh the cons
8. Summary of the guidelines for preventing opportunistic infections among hematopoietic stem cell transplant recipients
9. Effects of mutations in Pneumocystis carinii dihydropteroate synthase gene on outcome of AIDS-associated P. carinii pneumonia
10. Natural mode of acquisition for de novo infection with Pneumocystis carinii
11. Has the incidence of Pneumocystis carinii pneumonia in cancer patients increased with the AIDS epidemic?
12. Transmission of Pneumocystis carinii from AIDS patients: A cluster of Pneumocystis carinii pneumonia in renal tranplants
13. Transmission of Pneumocystis carinii DNA from a patient with P. carinii pneumonia to immunocompetent contact health care workers
14. Pneumocystis carinii f. sp. hominis DNA in immunocompetent health care workers in contact with patients with P. carinii pneumonia
15. Seasonal variation in presentation of Pneumocystis carinii pneumonia
16. Geographic variation in the humoral response to Pneumocystis carinii
17. A cluster of Pneumocystis carinii pneumonia in adults without predisposing illness
18. Pneumocystis carinii pneumonia in the United States
19. Five-year absence of Pneumocystis carinii pneumonia in a pediatric oncology center
20. Pneumocystis carinii pneumonia in patients without AIDS
21. Excess prevalence of Pneumocystis carinii pneumonia in patients treated for lymphoma with combination chemotherapy
22. Pneumocystis carinii pneumonia without acquired immunodeficiency syndrome
23. Pneumocystis carinii pneumonia in cancer patients
24. Combination chemotherapy of advanced non-Hodgkin lymphoma with bleomycin, adriamycin, cyclophosphamide, vincristine, and prednisone (BACOP)
25. Pulmonary complications associated with combination chemotherapy programs containing bleomycin
26. Infectious complications in chronic lymphocytic leukaemia
27. Pneumocystis carinii pneumonia among patients with neoplastic diseases
28. Pneumocystis carinii pneumonia in brain tumor patients: Risk factors and clinical features
29. Pneumocystis carinii pneumonia in patients receiving chemotherapy for breast cancer
30. Pneumocystis carinii pneumonia in breast cancer
31. Pneumocystis carinii infection in heart transplant recipients. Efficacy of a weekend prophylaxis schedule
32. Infectious complications of lung and heart-lung transplantation
33. Pneumocystis carinii pneumonia in renal-transplant recipients treated with cyclosporine and steroids
34. Breakthrough Pneumocystis carinii infections in lung and heart-lung transplant patients with chemoprophylaxis
35. Pneumocystis carinii pneumonia in heart transplant recipients
36. Pneumocystis carinii pneumonia in the course of connective tissue disease: Report of 34 cases
37. Pneumocystis carinii pneumonia: A major complication of immunosuppressive therapy in patients with Wegener's granulomatosis
38. Increased risk of Pneumocystis carinii pneumonia in patients with Wegner's granulomatosis
39. Pneumocystis carinii pneumonia in a patient with rheumatoid arthritis, not on immunosuppressive therapy and in the absence of human immunodeficiency virus infection
40. Patients with systemic lupus erythematosus at risk for Pneumocystis carinii pneumonia
41. Pneumocystis carinii pneumonia in childhood systemic lupus erythematosus
42. Intensity of immunosuppressive therapy and the incidence of Pneumocystis carinii pneumonitis
43. Pneumocystis carinii pneumonia developing within one month of intensive chemotherapy for treatment of acute lymphoblastic leukemia
44. When to initiate anti Pneumocystis carinii prophylaxis in acute lymphoblastic leukemia treatment?
45. Pneumocystis carinii pneumonia during steroid taper in patients with primary brain tumors
46. Relationship between enzymatic markers of pulmonary cell damage and cellular profile: A study in bronchoalveolar lavage fluid
47. Pulmonary colonization with Pneumocystis carinii in human immunodeficiency virus-negative patients: Assessing risk with blood CD4+ T cell counts
48. Pneumocystis carinii pneumonia associated with weekly methotrexate: Cumulative dose of methotrexate and low CD4 cell count may predict this complication
49. Pneumocystis carinii pneumonia in HIV-negative immunocompromised adults
50. Pneumocystis carinii pneumonia in patients without AIDS: 1980 through 1993
51. Pneumocystis carinii pneumonia. Review of 53 cases
52. Should prophylaxis for Pneumocystis carinii pneumonia in solid organ transplant recipients ever be discontinued?
53. Effectiveness of low-dose cotrimoxazole prophylaxis against Pneumocystis carinii pneumonia after renal and/or pancreas transplantation
54. Contribution of dihydropteroate synthase gene typing for Pneumocystis carinii f. sp. hominis epidemiology
55. High rates of Pneumocystis carinii pneumonia in allogenic blood and marrow transplant recipients receiving dapsone prophylaxis
56. Drug-resistant Pneumocystis carinii
57. Survival of patients with AIDS, after diagnosis of Pneumocystis carinii pneumonia, in the United States
58. Mutations in dihydropteroate synthase gene of Pneumocystis carinii in HIV patients with Pneumocystis carinii pneumonia
59. A meta-analysis of the relative efficacy and toxicity of Pneumocystis carinii prophylaxis regimens